These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? [Yahoo! Finance]
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: Yahoo! Finance
Nektar is developing an experimental eczema treatment. Millions of patients with stubbornly high blood pressure could benefit from an experimental drug being developed by Mineralys. 10 stocks we like better than Nektar Therapeutics › Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept. 19, shares of Nektar Therapeutics (NASDAQ: NKTR) and Mineralys Therapeutics (NASDAQ: MLYS) jumped more than 100% higher. Just because they're already risen sharply doesn't mean they can't keep climbing. Here's a look at what drove both drugmakers' stocks through the roof, and how they could continue to outperform. Image source: Getty Images. 1. Nektar Therapeutics From Aug. 18 through the first hour of trading on Sept. 18, shares of Nektar Therapeutics shot 108% higher. Investors have been cheering for the company's lead candidate, an IL-2 pathway agonist called rezpegaldesleukin. In a phase 2b study
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Nektar Therapeutics (NASDAQ:NKTR) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $102.00 price target on the stock.MarketBeat
- Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..MarketBeat
- How Recent Clinical Wins and Risks Are Changing the Story for Nektar Therapeutics [Yahoo! Finance]Yahoo! Finance
NKTR
Earnings
- 11/6/25 - Beat
NKTR
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- NKTR's page on the SEC website